Want to see ICU full AI Analyst Report?
ICU Stock Chart & Stats
$3.75
$0.04(1.07%)
At close: 4:00 PM EDT
$3.75
$0.04(1.07%)
Day’s Range― - ―
52-Week Range$2.07 - $12.50
Previous CloseN/A
Volume1.09K
Average Volume (3M)3.06M
Market Cap
$14.01M
Enterprise Value$8.16
Total Cash (Recent Filing)$6.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 18, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding4,406,841
10 Day Avg. Volume1,756,841
30 Day Avg. Volume3,057,972
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)4.78
Price to Sales (P/S)40.32
P/FCF Ratio-3.66
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.64
Revenue Forecast (FY)$1.95M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently >90% gross margins signal attractive unit economics typical of capital-plus-consumable device models. Durable high margins support scalability as volumes rise, cushion operating losses per incremental sale, and improve the pathway to positive operating leverage once commercial adoption broadens.
Early Commercial Traction And Customer AdditionsRapid percentage revenue growth and multiple new hospital adopters provide durable evidence of product-market fit in targeted clinical niches. Repeated orders and an expanding customer base reduce commercialization execution risk and create a foundation for a multi-quarter revenue ramp if enrollment and adoption continue.
Improved Liquidity And Low LeverageA stronger cash balance combined with minimal debt materially improves near-term runway and strategic optionality. Low leverage reduces insolvency risk and gives management flexibility to prioritize trial enrollment and targeted commercial investments without immediate pressure to refinance under stressed terms.
Bears Say
Heavy Cash BurnSustained ~-$13.7M annual cash outflow overwhelms current revenue, meaning the company must materially ramp sales or access external capital within months. Persistent negative cash flow elevates financing risk and can force dilutive capital raises or spending cuts that slow clinical and commercial progress.
Small Absolute Revenue BaseA sub-$0.5M quarterly revenue base keeps fixed costs outsized and makes forecasts highly sensitive to a few hospitals or cases. Structural reliance on a limited pediatric/ultra-rare patient flow means revenue volatility and slow scaling could persist, hampering sustainable margin conversion and cash self-sufficiency.
Significant Share DilutionLarge dilution materially reduces per-share economic recovery and shareholder returns even if operating results improve. Recurring dilution risk can depress incentives for long-term investors, complicate future raises, and require stronger operational performance to restore per-share value.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.07 and its highest was $12.50 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $14.01M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Nov 18, 2026 which is in 93 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on Aug 12, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.97 by $0.06.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Overvalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.9.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 4,406,841 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.97. Following the earnings report the stock price went down -5.655%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
ICU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented meaningful commercial and clinical progress: strong year-over-year revenue growth (+82% Q2), expanded hospital adoption (20 of top 50 pediatric centers), important regulatory and reimbursement milestones (Breakthrough Designation, ICD-10-PCS code), and solid enrollment progress in the NEUTRALIZE-AKI pivotal trial (~65.8% enrolled). Offsetting these positives are materially higher operating expenses, a larger net loss in absolute dollars, a notable cash decline (−41.7% from year-end 2025) and an enrollment cadence that is slower than ideal — all of which create near-term execution and funding risks. On balance, the trajectory is encouraging commercially and clinically, but the company must manage cash runway and accelerate enrollment to realize the larger adult opportunity.View all ICU earnings summariesTechnical Analysis
Ownership Overview
3.44% Insiders
1.20% Mutual Funds
<0.01% Other Institutional Investors
94.55% Public Companies and
Individual Investors